AI English summary of an SEC filing — figures as filed
Vertex Pharmaceuticals VRTXVertex said total revenue for Q2 2025 (the 3 months ended June 30, 2025) was $2.96 billion, a 12% increase compared to Q2 2024. The company cited continued performance of cystic fibrosis therapies and early contributions from the three ongoing product launches as factors for the increase.
Key points
AI summaryVertex said total revenue for Q2 2025 (the 3 months ended June 30, 2025) was $2.96 billion, a 12% increase compared to Q2 2024. The company cited continued performance of cystic fibrosis therapies and early contributions from the three ongoing product launches as factors for the increase.
Vertex reported GAAP net income of $1.0 billion and non-GAAP net income of $1.2 billion for Q2 2025, compared to net losses of $3.6 billion and $3.3 billion, respectively, for Q2 2024. The company said Q2 2024 included $4.4 billion of Acquired IPR&D expenses related to the Alpine Immune Sciences acquisition.
Vertex said cash, cash equivalents and total marketable securities as of June 30, 2025 were $12.0 billion, compared to $11.2 billion as of December 31, 2024. The company cited cash flows from operating activities as a factor for the increase, partially offset by repurchases of Vertex's common stock pursuant to its share repurchase programs and income tax payments.
Vertex reiterated its full year 2025 revenue guidance of $11.85 billion to $12 billion and its non-GAAP effective tax rate guidance of 20.5% to 21.5%. The company said in its guidance table that revenue, combined expenses and effective tax rate remained unchanged from prior guidance.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q2 2025 Total Revenue $2.96 billion
Vertex said total revenue for Q2 2025 (the 3 months ended June 30, 2025) was $2.96 billion, a 12% increase compared to Q2 2024. The company cited continued performance of cystic fibrosis therapies and early contributions from the three ongoing product launches as factors for the increase.
Source · Based on the filing body and exhibits
Q2 GAAP Net Income $1.0 billion Swing
Vertex reported GAAP net income of $1.0 billion and non-GAAP net income of $1.2 billion for Q2 2025, compared to net losses of $3.6 billion and $3.3 billion, respectively, for Q2 2024. The company said Q2 2024 included $4.4 billion of Acquired IPR&D expenses related to the Alpine Immune Sciences acquisition.
Source · Based on the filing body and exhibits
Cash and Marketable Securities $12.0 billion
Vertex said cash, cash equivalents and total marketable securities as of June 30, 2025 were $12.0 billion, compared to $11.2 billion as of December 31, 2024. The company cited cash flows from operating activities as a factor for the increase, partially offset by repurchases of Vertex's common stock pursuant to its share repurchase programs and income tax payments.
Source · Based on the filing body and exhibits
2025 Full-Year Guidance Reiterated
Vertex reiterated its full year 2025 revenue guidance of $11.85 billion to $12 billion and its non-GAAP effective tax rate guidance of 20.5% to 21.5%. The company said in its guidance table that revenue, combined expenses and effective tax rate remained unchanged from prior guidance.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…